Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Open in Screener

MIRM

Mirum Pharmaceuticals Inc

May 22 • 04:00PM ET

98.62

-2.05 -2.04 %

Healthcare • Biotechnology • USA • Mid • NASD

Peers: MDGL KRYS TVTX RYTM TGTX

| Held by: VTI XBI IWM VB VXF IBB VBK IWO SCHA VTWO

Index	RUT	P/E	-	EPS (ttm)	-13.60	Insider Own	18.68%	Shs Outstand	60.93M	Perf Week	-3.49%
Market Cap	6.01B	Forward P/E	-	EPS next Y	-0.60	Insider Trans	-0.94%	Shs Float	57.35M	Perf Month	7.25%
Enterprise Value	5.95B	PEG	-	EPS next Q	-0.76	Inst Own	95.36%	Short Float	14.67%	Perf Quarter	-6.87%
Income	-798.84M	P/S	10.56	EPS this Y	-3196.89%	Inst Trans	11.57%	Short Ratio	8.44	Perf Half Y	40.02%
Sales	569.61M	P/B	24.78	EPS next Y	96.13%	ROA	-101.04%	Short Interest	8.41M	Perf YTD	24.85%
Book/sh	3.98	P/C	15.57	EPS next 5Y	-	ROE	-335.82%	52W High	114.99 -14.24%	Perf Year	123.88%
Cash/sh	6.33	P/FCF	-	EPS past 3/5Y	51.26% 35.25%	ROIC	-141.66%	52W Low	42.89 129.94%	Perf 3Y	253.10%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	89.13% -	Gross Margin	81.32%	Volatility	5.57% 6.20%	Perf 5Y	462.90%
Dividend TTM	-	EV/Sales	10.45	EPS Y/Y TTM	-742.29%	Oper. Margin	-12.31%	ATR (14)	5.65	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	1.99	Sales Y/Y TTM	50.19%	Profit Margin	-140.24%	RSI (14)	48.26	Recom	1.08
Dividend Gr. 3/5Y	- -	Current Ratio	2.09	EPS Q/Q	-4372.49%	SMA20	-2.81%	Beta	0.50	Target Price	144.15
Payout	-	Debt/Eq	1.34	Sales Q/Q	43.28%	SMA50	2.12%	Rel Volume	0.45	Prev Close	100.67
Employees	372	LT Debt/Eq	1.33	Earnings	May 06 AMC	SMA200	18.06%	Avg Volume	997.03K	Price	98.62
IPO	Jul 18, 2019	Option/Short	Yes / Yes	EPS/Sales Surpr.	-3576.43% 7.89%	Trades		Volume	452,999	Change	-2.04%

Date	Action	Analyst	Rating Change	Price Target Change
May-19-26	Initiated	Wolfe Research	Outperform	$145
Feb-18-26	Initiated	RBC Capital Mkts	Outperform	$130
Sep-24-25	Initiated	TD Cowen	Buy	$95
Aug-11-25	Resumed	Stifel	Buy	$89
May-19-25	Resumed	H.C. Wainwright	Buy	$73
Apr-17-24	Initiated	Stifel	Buy	$48
Dec-18-23	Reiterated	H.C. Wainwright	Buy	$60 → $58
Nov-20-23	Resumed	JP Morgan	Overweight	$37
Nov-13-23	Initiated	Morgan Stanley	Overweight	$60
Oct-24-23	Initiated	Cantor Fitzgerald	Overweight	$50
Oct-17-23	Resumed	Evercore ISI	Outperform	$62
Sep-20-23	Initiated	JMP Securities	Mkt Outperform	$70
Sep-01-22	Initiated	Citigroup	Buy	$38
Sep-20-21	Initiated	JP Morgan	Overweight	$30
Aug-07-20	Upgrade	Raymond James	Outperform → Strong Buy	$28 → $48
Aug-03-20	Initiated	H.C. Wainwright	Buy	$52
Jul-31-20	Initiated	Piper Sandler	Overweight	$77
Jun-25-20	Initiated	Robert W. Baird	Outperform	$30
Aug-12-19	Initiated	ROTH Capital	Buy	$33
Aug-12-19	Initiated	Raymond James	Outperform	$28

Show Previous Ratings

May-21-26 08:05AM	Mirum Pharmaceuticals to Present Data Showcasing Leadership in Rare Liver Diseases at the EASL International Liver Congress 2026 (Business Wire)
May-14-26 04:01PM	Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -8.26%
May-12-26 11:56PM	Mirum Pharmaceuticals Prices $600.0 Million Convertible Senior Notes Offering; Refinances a Portion of 2029 Convertible Notes (Business Wire)
04:01PM	Mirum Pharmaceuticals Announces Proposed Convertible Senior Notes Offering (Business Wire)
08:00AM	Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences (Business Wire)
08:29PM	Loading…
May-06-26 08:29PM	Mirum Pharmaceuticals, Inc. Q1 2026 Earnings Call Summary (Moby) -6.50%
04:01PM	Mirum Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update (Business Wire)
May-05-26 08:59AM	Idexx Claws Down A Beat As Shares Bound Higher On A Guidance Hike (Investor's Business Daily)
May-04-26 12:59PM	Why This Biotech ETF - The IBD Stock Of The Day - Just Reentered Its Buy Zone (Investor's Business Daily) +9.59%
12:05PM	The $1 Billion-Plus Opportunity That Sent Mirum Pharma Catapulting To A Record (Investor's Business Daily)
08:00AM	Mirum Pharmaceuticals Announces Primary Endpoint Met in VISTAS Study of Volixibat in Patients with Primary Sclerosing Cholangitis (Business Wire)
May-03-26 05:00PM	Mirum Pharmaceuticals to Host Investor Call to Share Topline Results from the VISTAS Study of Volixibat in Patients with Primary Sclerosing Cholangitis on May 4, 2026 (Business Wire)
Apr-29-26 04:01PM	Mirum Pharmaceuticals to Announce First Quarter 2026 Financial Results and Host Conference Call on May 6, 2026 (Business Wire)
Apr-27-26 08:00AM	Mirum Pharmaceuticals Announces Primary Endpoint Met in Phase 2b Portion of the AZURE-1 Study of Brelovitug in Chronic Hepatitis Delta Virus (Business Wire)
Mar-16-26 08:00AM	Mirum Pharmaceuticals Completes Enrollment in Phase 3 EXPAND Study of LIVMARLI (maralixibat) in Additional Rare Cholestatic Liver Diseases (Business Wire)
05:30PM	Loading…
Mar-12-26 05:30PM	Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Mar-06-26 08:27AM	Mirum Completes Enrollment & Screening in Liver Disease Studies (Zacks)
Mar-05-26 08:00AM	Mirum Pharmaceuticals Provides AZURE Clinical Program Update for brelovitug in Chronic Hepatitis Delta Virus (Business Wire) -5.59%
Feb-26-26 10:50AM	Mirum's Q4 Earnings Lag, Higher Product Sales Drive Y/Y Revenues (Zacks) -15.13%
12:04AM	Mirum Pharmaceuticals Inc (MIRM) Q4 2025 Earnings Call Highlights: Record Sales and Strategic ... (GuruFocus.com)
Feb-25-26 08:00PM	Mirum Pharmaceuticals (MIRM) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates (Zacks)
07:25PM	Mirum Pharmaceuticals, Inc. (MIRM) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
05:25PM	Mirum Pharmaceuticals Q4 Earnings Call Highlights (MarketBeat)
04:01PM	Mirum Pharmaceuticals Reports Fourth Quarter and Year-End 2025 Results and Provides Business Update (Business Wire)
Feb-23-26 07:25PM	Tarsus Pharmaceuticals, Inc. (TARS) Reports Q4 Loss, Beats Revenue Estimates (Zacks)
04:01PM	Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences (Business Wire)
10:00AM	TG Therapeutics (TGTX) Earnings Expected to Grow: What to Know Ahead of Q4 Release (Zacks)
Feb-19-26 06:03AM	ImmunityBio (IBRX) Moves 41.9% Higher: Will This Strength Last? (Zacks)
Feb-18-26 04:01PM	Mirum Pharmaceuticals to Announce Fourth Quarter and Year-End 2025 Financial Results and Host Conference Call on February 25, 2026 (Business Wire)
10:00AM	Mirum Pharmaceuticals, Inc. (MIRM) Earnings Expected to Grow: What to Know Ahead of Q4 Release (Zacks)
10:45PM	Loading…
Feb-10-26 10:45PM	Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Feb-05-26 08:51AM	Mirum Pharmaceuticals Announces Health Canada Authorization of LIVMARLI Tablet Formulation for the Treatment of Cholestatic Pruritus in Patients with Alagille Syndrome (Business Wire) -5.51%
08:00AM	Mirum Pharmaceuticals Announces Health Canada Authorization of LIVMARLI for the Treatment of Cholestatic Pruritus in Patients with Progressive Familial Intrahepatic Cholestasis (PFIC) (Business Wire)
Feb-03-26 02:10AM	Mirum doubles down on diversified rare disease strategy (Pharma Voice)
Jan-31-26 03:22PM	Is Mirum Pharmaceuticals on a Strong Path to Profitability? (Motley Fool)
08:15AM	Insiders Are Still Scooping Up Under Armour and WR Berkley Shares (24/7 Wall St.)
Jan-29-26 02:27PM	H.C. Wainwright Raises PT on Mirum Pharmaceuticals For the Second Time In a Span of Two Weeks, Here is Why? (Insider Monkey)
Jan-27-26 06:33AM	Mirum acquires Bluejay Therapeutics to expand rare liver disease pipeline (Pharmaceutical Technology)
03:15AM	Is Mirum Pharmaceuticals About to Soar in 2026? (Motley Fool)
Jan-26-26 08:00AM	Mirum Pharmaceuticals Completes Acquisition of Bluejay Therapeutics, Expanding Global Leadership in Rare Disease (Business Wire)
Jan-22-26 09:52PM	Baird Updates Mirum Pharmaceuticals (MIRM) Valuation Following Beat-and-Raise Earnings Results (Insider Monkey)
Jan-20-26 09:38AM	CorMedix vs. Mirum Pharma: Which Rare-Disease Stock is the Better Buy? (Zacks)
Jan-16-26 11:08AM	Mirum Stock Rises 7% in a Week: Here's What You Should Know (Zacks)
Jan-13-26 05:04AM	3 Top Growth Stocks to Buy in the First Half of 2026 (Motley Fool)
Jan-12-26 05:30PM	Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
08:30AM	Mirum Pharmaceuticals Announces Preliminary Unaudited 2025 Results, Demonstrating Strong Commercial Growth and Pipeline Momentum (Business Wire)
Jan-09-26 11:55AM	Enthorin Therapeutics Announces Initiation of Phase II Clinical Trial of MRM-3379 (Formerly ENT-3379) for Fragile X Syndrome by Licensing Partner Mirum Pharmaceuticals (Business Wire) +6.09%
Jan-07-26 04:01PM	Mirum Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference (Business Wire) +7.22%
Jan-06-26 08:03AM	Should You Invest in Mirum Pharmaceuticals (MIRM)? (Insider Monkey)
Jan-04-26 04:05AM	5 Predictions for the Stock Market in 2026 -- and Which Stocks Will Soar the Most If They're Right (Motley Fool)
Dec-30-25 03:07AM	Prediction: 3 Stocks That Will Be Worth More Than Newsmax 5 Years From Now (Motley Fool)
Dec-23-25 01:52PM	This Biotech Name Outperforms 93% Of Stocks, And It's In A Buy Zone (Investor's Business Daily)
Dec-19-25 08:30AM	Mirum Pharmaceuticals Announces Additional Private Placement Financing With TCGX (Business Wire) +10.61%
Dec-18-25 10:41AM	Will Strong Livmarli Uptake Continue to Aid MIRM's Revenues in 2026? (Zacks)
Dec-11-25 07:44AM	Morgan Stanley Raises Mirum (MIRM) PT to $95 on Strategic Bluejay Acquisition, Brelovitug Pipeline Addition (Insider Monkey)
Dec-09-25 09:45AM	Mirum Pharmaceuticals price target raised to $130 from $95 at Cantor Fitzgerald (TipRanks)
09:42AM	Mirum to buy Bluejay for up to $820m in rare liver disease push (Pharmaceutical Technology)
Dec-08-25 08:31AM	Mirum gains a hepatitis D drug in $620M buyout of startup Bluejay (BioPharma Dive)
08:00AM	Mirum Pharmaceuticals Enters into Definitive Agreement to Acquire Bluejay Therapeutics, Expanding Global Leadership in Rare Disease (Business Wire)
Dec-04-25 11:30AM	Mirum Pharmaceuticals (MIRM) Up 1.3% Since Last Earnings Report: Can It Continue? (Zacks)
Dec-03-25 06:30AM	Prediction: This Stock Has Soared Nearly 70% in 2025 and Will Be an Even Bigger Winner in 2026 (Motley Fool)
Dec-02-25 10:15AM	MIRM Enrolls First Patient in Phase II Fragile X Syndrome Study (Zacks)
Dec-01-25 08:10AM	Mirum Pharmaceuticals Announces First Patient Enrolled in the BLOOM Phase 2 Clinical Study Evaluating MRM-3379 in Fragile X Syndrome (Business Wire)
Nov-28-25 10:07AM	Biotechs Are On A Big Run, And Two Stocks Have Buy Points (Investor's Business Daily)
Nov-25-25 04:02PM	Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences (Business Wire)
Nov-10-25 08:00PM	Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Nov-07-25 08:10AM	Mirum Pharmaceuticals Showcases Leadership in Liver Disease Innovation With Data From LIVMARLI and Volixibat Clinical Programs at AASLDs The Liver Meeting (Business Wire)
Nov-05-25 11:27AM	MIRM's Q3 Earnings & Revenues Beat Estimates, 2025 View Tightened (Zacks)
12:04AM	Mirum Pharmaceuticals Inc (MIRM) Q3 2025 Earnings Call Highlights: Strong Revenue Growth and ... (GuruFocus.com)
Nov-04-25 05:10PM	Mirum Pharmaceuticals, Inc. (MIRM) Surpasses Q3 Earnings and Revenue Estimates (Zacks)
04:01PM	Mirum Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update (Business Wire)
Nov-03-25 04:05PM	Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences (Business Wire)
Oct-29-25 10:00AM	Techne (TECH) Reports Next Week: What to Know Ahead of the Release (Zacks)
Oct-28-25 04:02PM	Mirum Pharmaceuticals to Announce Third Quarter 2025 Financial Results and Host Conference Call on November 4, 2025 (Business Wire)
Oct-14-25 10:56AM	Will Livmarli Continue to Drive Mirum's Top Line in Q3 Earnings? (Zacks)
Oct-10-25 07:45PM	Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Sep-23-25 10:44AM	CRMD vs. MIRM: Which Specialized Biotech Stock is the Better Pick? (Zacks)
Sep-10-25 06:45PM	Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Sep-08-25 08:00AM	Mirum Pharmaceuticals Announces Enrollment Completion in the Phase 2b VISTAS Study (Business Wire)
Aug-27-25 04:02PM	Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences (Business Wire)
Aug-11-25 05:31PM	IBAT Inhibitors Market Witnesses Strong Growth During the Forecast Period (2025-2034) Owing to the Rising Demand for Rare Cholestatic Liver Disease Therapies \| DelveInsight (PR Newswire) +9.84%
09:33AM	Arm initiated, Adobe downgraded: Wall Street's top analyst calls (The Fly)
Aug-07-25 11:20AM	MIRM Stock Up on Q2 Earnings and Revenue Beat, Raised 2025 View (Zacks) +12.04%
Aug-06-25 05:55PM	Mirum Pharmaceuticals, Inc. (MIRM) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
04:01PM	Mirum Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update (Business Wire)
Jul-31-25 07:40AM	Agios Pharmaceuticals (AGIO) Reports Q2 Loss, Beats Revenue Estimates (Zacks)
Jul-30-25 04:01PM	Mirum Pharmaceuticals to Announce Second Quarter 2025 Financial Results and Host Conference Call on August 6, 2025 (Business Wire)
10:00AM	Mirum Pharmaceuticals, Inc. (MIRM) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release (Zacks)
Jul-17-25 10:02AM	Mirum Gains 35% in 3 Months: How Should You Play the Stock? (Zacks)
Jul-10-25 06:15PM	Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jun-24-25 12:15PM	EMA Accepts GSK's Filing for Linerixibat in Rare Disease-Related Itch (Zacks)
Jun-17-25 12:36PM	Liver Drug Stock Rockets 236% Amid FDA Approval As Sales Accelerate; Funds Load Up (Investor's Business Daily)
Jun-13-25 01:57PM	CoreWeave Leads Four Stocks Near Buy Points; One Is Also An Nvidia Partner (Investor's Business Daily)
Jun-11-25 11:30AM	Why Is Editas (EDIT) Up 40% Since Last Earnings Report? (Zacks)
Jun-10-25 08:40PM	Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jun-06-25 11:31AM	Why Is Mirum Pharmaceuticals (MIRM) Down 1.3% Since Last Earnings Report? (Zacks)
Jun-03-25 11:41AM	FDA Accepts GSK's NDA for Linerixibat in Rare Disease-Related Itch (Zacks)
May-19-25 08:30AM	Mirum Pharmaceuticals Appoints Doug Sheehy, JD, as Chief Legal Officer (Business Wire)
May-14-25 04:05PM	Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences (Business Wire)
May-09-25 06:00PM	Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)

Mirum Pharmaceuticals, Inc. is a biopharmaceutical company. The firm focuses on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. Its products include Maralixibat and Volixibat. The company was founded by Niall O'Donnel, Michael Grey and Christopher Peetz in May 2018 and is headquartered in Foster City, CA.

CEO & DirectorMr. Christopher Peetz

Ph.D.Mr. Peter Radovich M.B.A.

M.S.Mr. Eric H. Bjerkholt M.B.A.

Chief Medical OfficerDr. Joanne M. J. Quan M.D.

Chief Technical OfficerDr. Jean-Luc Girardet Ph.D.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Ramasastry Saira	Director	May 15 '26	Option Exercise	23.51	2,000	47,020	2,000	May 18 08:32 PM
Ramasastry Saira	Director	May 15 '26	Sale	109.47	2,000	218,940	0	May 18 08:32 PM
SAIRA RAMASASTRY	Director	May 15 '26	Proposed Sale	109.47	2,000	218,940		May 15 04:07 PM
Ramasastry Saira	Director	Apr 15 '26	Option Exercise	23.51	2,000	47,020	2,000	Apr 16 08:40 PM
Ramasastry Saira	Director	Apr 15 '26	Sale	96.90	2,000	193,800	0	Apr 16 08:40 PM
SAIRA RAMASASTRY	Director	Apr 15 '26	Proposed Sale	96.90	2,000	193,800		Apr 15 04:11 PM
BJERKHOLT ERIC	CHIEF FINANCIAL OFFICER	Mar 16 '26	Sale	91.98	7,287	670,243	49,788	Mar 17 07:30 PM
Quan Joanne	CHIEF MEDICAL OFFICER	Mar 16 '26	Sale	91.98	7,287	670,243	18,864	Mar 17 07:30 PM
Ramasastry Saira	Director	Mar 16 '26	Option Exercise	23.51	2,000	47,020	2,000	Mar 17 07:30 PM
Ramasastry Saira	Director	Mar 16 '26	Sale	90.76	2,000	181,520	0	Mar 17 07:30 PM
Radovich Peter	PRESIDENT AND COO	Mar 16 '26	Sale	91.98	16,515	1,519,015	40,272	Mar 17 07:30 PM
Howe Jolanda	SVP, GLOBAL CONTROLLER	Mar 16 '26	Sale	91.98	4,732	435,239	8,429	Mar 17 07:30 PM
Peetz Christopher	CHIEF EXECUTIVE OFFICER	Mar 16 '26	Sale	91.98	40,985	3,769,714	194,309	Mar 17 07:30 PM
ERIC BJERKHOLT	Officer	Mar 16 '26	Proposed Sale	92.64	7,287	675,068		Mar 17 07:03 PM
Joanne Quan	Officer	Mar 16 '26	Proposed Sale	92.64	7,287	675,068		Mar 17 07:00 PM
Peter Radovich	Officer	Mar 16 '26	Proposed Sale	92.64	16,515	1,529,950		Mar 17 06:58 PM
Jolanda Howe	Officer	Mar 16 '26	Proposed Sale	92.64	4,732	438,372		Mar 17 06:55 PM
Christopher Peetz	Officer	Mar 16 '26	Proposed Sale	92.64	40,985	3,796,850		Mar 17 06:50 PM
SAIRA RAMASASTRY	Director	Mar 16 '26	Proposed Sale	90.76	2,000	181,520		Mar 16 04:04 PM
Radovich Peter	PRESIDENT AND COO	Mar 06 '26	Option Exercise	15.87	5,912	93,823	26,567	Mar 11 04:05 PM
Ramasastry Saira	Director	Feb 13 '26	Option Exercise	23.51	2,000	47,020	2,000	Feb 17 04:38 PM
Ramasastry Saira	Director	Feb 13 '26	Sale	102.09	2,000	204,180	0	Feb 17 04:38 PM
SAIRA RAMASASTRY	Director	Feb 13 '26	Proposed Sale	102.09	2,000	204,180		Feb 13 04:04 PM
Radovich Peter	PRESIDENT AND COO	Feb 02 '26	Sale	103.30	2,631	271,792	20,655	Feb 03 09:45 PM
Peetz Christopher	CHIEF EXECUTIVE OFFICER	Feb 02 '26	Sale	103.30	9,108	940,888	160,294	Feb 03 09:45 PM
Howe Jolanda	SVP, GLOBAL CONTROLLER	Feb 02 '26	Sale	103.30	968	99,998	4,503	Feb 03 09:45 PM
Jolanda Howe	Officer	Feb 02 '26	Proposed Sale	103.80	968	100,478		Feb 02 08:29 PM
Peter Radovich	Officer	Feb 02 '26	Proposed Sale	103.80	2,631	273,098		Feb 02 08:25 PM
Christopher Peetz	Officer	Feb 02 '26	Proposed Sale	103.80	9,108	945,410		Feb 02 08:21 PM
Jolanda Howe	Officer	Jan 26 '26	Proposed Sale	96.92	842	81,607		Jan 28 06:47 PM
ERIC BJERKHOLT	Officer	Jan 26 '26	Proposed Sale	96.92	1,053	102,057		Jan 28 06:44 PM
Peter Radovich	Officer	Jan 26 '26	Proposed Sale	96.92	3,143	304,620		Jan 28 06:43 PM
Christopher Peetz	Officer	Jan 26 '26	Proposed Sale	96.92	6,831	662,061		Jan 28 06:40 PM
BJERKHOLT ERIC	CHIEF FINANCIAL OFFICER	Jan 26 '26	Sale	96.19	1,053	101,290	43,741	Jan 27 04:30 PM
Radovich Peter	PRESIDENT AND COO	Jan 26 '26	Sale	96.19	3,143	302,331	23,286	Jan 27 04:30 PM
Howe Jolanda	SVP, GLOBAL CONTROLLER	Jan 26 '26	Sale	96.19	842	80,994	3,700	Jan 27 04:30 PM
Peetz Christopher	CHIEF EXECUTIVE OFFICER	Jan 26 '26	Sale	96.19	6,831	657,088	169,402	Jan 27 04:30 PM
Heron Patrick J	Director	Jan 23 '26	Buy	68.48	131,425	8,999,984	459,010	Jan 27 04:14 PM
Howe Jolanda	SVP, GLOBAL CONTROLLER	Jan 22 '26	Sale	93.33	926	86,419	3,042	Jan 23 05:30 PM
Quan Joanne	CHIEF MEDICAL OFFICER	Jan 22 '26	Sale	93.33	1,822	170,039	12,817	Jan 23 05:30 PM
BJERKHOLT ERIC	CHIEF FINANCIAL OFFICER	Jan 22 '26	Sale	93.33	1,421	132,615	42,127	Jan 23 05:30 PM
Radovich Peter	PRESIDENT AND COO	Jan 22 '26	Sale	93.33	2,382	222,301	20,679	Jan 23 05:30 PM
Peetz Christopher	CHIEF EXECUTIVE OFFICER	Jan 22 '26	Sale	93.33	7,098	662,422	163,733	Jan 23 05:30 PM
Quan Joanne	CHIEF MEDICAL OFFICER	Jan 20 '26	Sale	90.27	6,911	623,853	11,305	Jan 21 04:05 PM
Ramasastry Saira	Director	Jan 15 '26	Option Exercise	23.51	2,000	47,020	2,000	Jan 16 04:05 PM
Ramasastry Saira	Director	Jan 15 '26	Sale	90.99	2,000	181,980	0	Jan 16 04:05 PM
SAIRA RAMASASTRY	Director	Jan 15 '26	Proposed Sale	90.99	2,000	181,980		Jan 15 04:02 PM
Ramasastry Saira	Director	Dec 22 '25	Option Exercise	23.51	5,000	117,550	5,000	Dec 23 06:52 PM
Ramasastry Saira	Director	Dec 22 '25	Sale	80.00	5,000	400,000	0	Dec 23 06:52 PM
GREY MICHAEL G	Director	Dec 19 '25	Option Exercise	2.94	50,000	146,800	50,000	Dec 23 06:50 PM
GREY MICHAEL G	Director	Dec 19 '25	Sale	78.00	50,000	3,900,000	0	Dec 23 06:50 PM
SAIRA RAMASASTRY	Director	Dec 22 '25	Proposed Sale	80.00	5,000	400,000		Dec 22 04:03 PM
Ramasastry Saira	Director	Dec 18 '25	Option Exercise	23.51	2,000	47,020	2,000	Dec 19 04:15 PM
Ramasastry Saira	Director	Dec 18 '25	Sale	69.73	2,000	139,460	0	Dec 19 04:15 PM
MICHAEL GREY	Director	Dec 19 '25	Proposed Sale	78.00	50,000	3,900,000		Dec 19 04:05 PM
SAIRA RAMASASTRY	Director	Dec 18 '25	Proposed Sale	69.73	2,000	139,460		Dec 18 04:09 PM
GREY MICHAEL G	Director	Dec 01 '25	Option Exercise	2.94	50,000	146,800	50,000	Dec 02 04:04 PM
GREY MICHAEL G	Director	Dec 01 '25	Sale	74.00	50,000	3,700,000	0	Dec 02 04:04 PM
MICHAEL GREY	Director	Dec 01 '25	Proposed Sale	74.00	50,000	3,700,000		Dec 01 04:07 PM
GREY MICHAEL G	Director	Nov 21 '25	Option Exercise	2.94	50,000	146,800	50,000	Nov 25 04:10 PM
GREY MICHAEL G	Director	Nov 21 '25	Sale	70.00	50,000	3,500,000	0	Nov 25 04:10 PM
MICHAEL GREY	Director	Nov 21 '25	Proposed Sale	70.00	50,000	3,500,000		Nov 21 04:09 PM
Peetz Christopher	CHIEF EXECUTIVE OFFICER	Nov 18 '25	Option Exercise	19.24	19,133	368,119	158,034	Nov 20 04:21 PM
Brege Laura	Director	Sep 11 '25	Option Exercise	15.00	17,000	255,000	32,703	Sep 12 08:00 PM
Brege Laura	Director	Sep 11 '25	Sale	74.40	17,000	1,264,868	15,703	Sep 12 08:00 PM
BJERKHOLT ERIC	CHIEF FINANCIAL OFFICER	Sep 12 '25	Sale	76.01	9,578	728,024	39,945	Sep 12 08:00 PM
LAURA BREGE	Director	Sep 11 '25	Proposed Sale	74.41	17,000	1,264,917		Sep 11 04:04 PM
Ramasastry Saira	Director	Sep 08 '25	Option Exercise	23.51	17,000	399,670	17,000	Sep 10 05:50 PM
SAIRA RAMASASTRY	Director	Sep 08 '25	Proposed Sale	77.04	17,000	1,309,716		Sep 08 04:06 PM
BJERKHOLT ERIC	CHIEF FINANCIAL OFFICER	Aug 12 '25	Option Exercise	26.49	2,954	78,251	31,190	Aug 12 08:00 PM
Peetz Christopher	CHIEF EXECUTIVE OFFICER	Aug 11 '25	Option Exercise	2.94	40,000	117,440	178,641	Aug 12 07:57 PM
Peetz Christopher	CHIEF EXECUTIVE OFFICER	Aug 11 '25	Sale	62.00	40,000	2,480,000	138,641	Aug 12 07:57 PM
CHRISTOPHER PEETZ	Officer	Aug 11 '25	Proposed Sale	62.00	40,000	2,480,000		Aug 11 04:06 PM
Howe Jolanda	SVP, GLOBAL CONTROLLER	Aug 07 '25	Option Exercise	6.27	10,000	62,700	12,426	Aug 08 04:50 PM
Howe Jolanda	SVP, GLOBAL CONTROLLER	Aug 07 '25	Sale	58.00	10,000	580,000	2,426	Aug 08 04:50 PM
Peetz Christopher	CHIEF EXECUTIVE OFFICER	Aug 07 '25	Option Exercise	2.94	40,000	117,440	178,641	Aug 08 04:49 PM
Peetz Christopher	CHIEF EXECUTIVE OFFICER	Aug 07 '25	Sale	55.25	40,000	2,210,040	138,641	Aug 08 04:49 PM
JOLANDA MARIE HOWE	Officer	Aug 07 '25	Proposed Sale	58.00	10,000	580,000		Aug 07 04:26 PM
CHRISTOPHER PEETZ	Officer	Aug 07 '25	Proposed Sale	55.25	40,000	2,210,040		Aug 07 04:25 PM
Howe Jolanda	SVP, GLOBAL CONTROLLER	Jul 02 '25	Sale	48.25	564	27,213	2,903	Jul 03 06:48 PM
Howe Jolanda	SVP, GLOBAL CONTROLLER	Jul 03 '25	Sale	49.08	477	23,411	2,426	Jul 03 06:48 PM
JOLANDA MARIE HOWE	Officer	Jul 03 '25	Proposed Sale	49.08	477	23,411		Jul 03 01:13 PM
Fairey William	Director	Jun 11 '25	Sale	48.42	3,203	155,091	2,500	Jun 13 04:18 PM
WILLIAM C FAIREY	Director	Jun 11 '25	Proposed Sale	48.42	3,203	155,091		Jun 11 04:05 PM
Ramasastry Saira	Director	Jun 03 '25	Option Exercise	14.12	2,500	35,300	2,500	Jun 04 04:11 PM
Ramasastry Saira	Director	Jun 02 '25	Sale	46.20	5,703	263,492	0	Jun 04 04:11 PM
Ramasastry Saira	Director	Jun 03 '25	Sale	45.74	2,500	114,352	0	Jun 04 04:11 PM
SAIRA RAMASASTRY	Director	Jun 03 '25	Proposed Sale	45.74	2,500	114,352		Jun 03 05:07 PM
SAIRA RAMASASTRY	Director	Jun 02 '25	Proposed Sale	46.20	5,703	263,492		Jun 02 06:43 PM

Open in Screener

MBX

MBX Biosciences Inc

May 22 • 04:00PM ET

31.85

+0.06 0.19 %

Healthcare • Biotechnology • USA • Small • NASD

MBX MBX Biosciences Inc daily Stock Chart

Peers: VKTX ALT RYTM TERN MDGL

| Held by: VTI IWM VXF IWN XPH IBB VTWO SCHA IWC FESM

Index	RUT	P/E	-	EPS (ttm)	-2.21	Insider Own	38.06%	Shs Outstand	47.57M	Perf Week	-1.85%
Market Cap	1.52B	Forward P/E	-	EPS next Y	-3.91	Insider Trans	-0.29%	Shs Float	29.45M	Perf Month	-4.61%
Enterprise Value	1.08B	PEG	-	EPS next Q	-0.64	Inst Own	75.62%	Short Float	13.70%	Perf Quarter	-13.33%
Income	-86.61M	P/S	-	EPS this Y	-17.75%	Inst Trans	11.87%	Short Ratio	6.98	Perf Half Y	16.28%
Sales	0.00M	P/B	3.46	EPS next Y	-39.37%	ROA	-24.79%	Short Interest	4.03M	Perf YTD	0.98%
Book/sh	9.20	P/C	3.45	EPS next 5Y	-20.53%	ROE	-25.73%	52W High	45.85 -30.53%	Perf Year	154.60%
Cash/sh	9.24	P/FCF	-	EPS past 3/5Y	-44.91% -	ROIC	-19.77%	52W Low	9.43 237.75%	Perf 3Y	-
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	5.79% 8.88%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-0.43%	Oper. Margin	-	ATR (14)	2.66	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	30.79	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	47.33	Recom	1.42
Dividend Gr. 3/5Y	- -	Current Ratio	30.79	EPS Q/Q	29.35%	SMA20	-2.79%	Beta	0.78	Target Price	69.09
Payout	-	Debt/Eq	0.00	Sales Q/Q	-	SMA50	0.73%	Rel Volume	0.75	Prev Close	31.79
Employees	63	LT Debt/Eq	0.00	Earnings	May 07 BMO	SMA200	18.97%	Avg Volume	577.47K	Price	31.85
IPO	Sep 13, 2024	Option/Short	Yes / Yes	EPS/Sales Surpr.	12.78% -	Trades		Volume	436,031	Change	0.19%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-28-26	Initiated	Barclays	Overweight	$66
Dec-04-25	Initiated	Goldman	Sell	$18
Nov-04-25	Initiated	TD Cowen	Buy
Oct-15-25	Initiated	Truist	Buy	$50
Aug-15-25	Resumed	Jefferies	Buy	$36
Aug-05-25	Initiated	Mizuho	Outperform	$38
Jul-16-25	Initiated	Oppenheimer	Outperform	$38
Apr-10-25	Initiated	Citizens JMP	Mkt Outperform	$38
Oct-08-24	Initiated	Stifel	Buy	$40
Oct-08-24	Initiated	JP Morgan	Overweight	$30
Oct-08-24	Initiated	Jefferies	Buy	$35
Oct-08-24	Initiated	Guggenheim	Buy	$44

Show Previous Ratings

Today 08:00AM	MBX Biosciences to Present at the Jefferies 2026 Global Healthcare Conference in New York City (GlobeNewswire)
May-11-26 07:00AM	MBX Biosciences Provides Obesity Portfolio Update Including Initial Phase 1 Data for MBX 4291 Supporting Potential for Once-Monthly Dosing (GlobeNewswire)
May-07-26 08:00AM	MBX Biosciences Reports First Quarter 2026 Financial Results and Corporate Highlights (GlobeNewswire) +8.06%
07:00AM	MBX Biosciences Announces Appointment of Mark Soued as Chief Commercial Officer and Inducement Grant Award (GlobeNewswire)
Apr-23-26 08:00AM	MBX Biosciences to Host In-Person and Virtual Obesity Day on May 11, 2026 to Discuss Expanding Obesity Portfolio (GlobeNewswire)
08:00AM	Loading…
Apr-03-26 08:00AM	MBX Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Mar-12-26 08:00AM	MBX Biosciences Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Corporate Highlights (GlobeNewswire)
Mar-10-26 08:00AM	MBX Biosciences Appoints Karen Basbaum as Chief Business Officer (GlobeNewswire)
Mar-09-26 10:21AM	CORRECTING & REPLACING -- MBX Biosciences Announces Successful End-of-Phase 2 FDA Meeting and Provides Phase 3 Development Plan for Once-Weekly Canvuparatide for Hypoparathyroidism (GlobeNewswire) -8.54%
08:00AM	MBX Biosciences Announces Successful End-of-Phase 2 FDA Meeting and Provides Phase 3 Development Plan for Once-Weekly Canvuparatide for Hypoparathyroidism (GlobeNewswire)
Feb-28-26 07:05PM	MBX Biosciences Calls 2026 Pivotal With Phase 3 Plans, Obesity Program, and $460M Cash Runway (MarketBeat)
Feb-23-26 08:00AM	MBX Biosciences to Participate in Upcoming March Investor Conferences (GlobeNewswire) +5.63%
Feb-20-26 06:53PM	TripAdvisor, Orthofix Medical, and More Stocks See Action From Activist Investors (Barrons.com) -6.63%
Feb-11-26 08:00AM	MBX Biosciences to Participate in Upcoming Investor Conferences (GlobeNewswire) -7.11%
Jan-22-26 08:00AM	MBX Biosciences Appoints Laurie Stelzer to Board of Directors as Audit Committee Chair (GlobeNewswire)
04:00PM	Loading…
Jan-11-26 04:00PM	MBX Biosciences to Provide 2026 Outlook and Business Update at 44th Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-15-25 11:11PM	MBX Biosciences (MBX) Faces Platform Validation Challenge as Near-Term Hypoglycemia Data Catalyst in Q2 2026 May Lack Differentiation (Insider Monkey)
08:00AM	MBX Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 13 (GlobeNewswire)
Dec-01-25 09:55AM	How Much Upside is Left in MBX Biosciences, Inc. (MBX)? Wall Street Analysts Think 80.6% (Zacks)
09:20AM	Take the Zacks Approach to Beat the Markets: MBX Biosciences, Garrett Motion & Monster Beverage in Focus (Zacks)
Nov-18-25 08:00AM	MBX Biosciences to Participate in the 37th Annual Piper Sandler Healthcare Conference (GlobeNewswire)
Nov-14-25 09:55AM	Wall Street Analysts See a 142% Upside in MBX Biosciences, Inc. (MBX): Can the Stock Really Move This High? (Zacks)
Nov-06-25 08:00AM	MBX Biosciences Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights (GlobeNewswire) +9.71%
Nov-04-25 09:35AM	DraftKings, Flutter downgraded: Wall Street's top analyst calls (The Fly)
Oct-29-25 09:55AM	Wall Street Analysts Think MBX Biosciences, Inc. (MBX) Could Surge 228.51%: Read This Before Placing a Bet (Zacks) +8.69%
Oct-20-25 08:00AM	MBX Biosciences to Participate in November Investor Conferences (GlobeNewswire) +7.64%
Oct-10-25 06:20PM	8Dell, 89bio, MBX Biosciences and More Stocks See Action From Activist Investors (Barrons.com) -5.99%
Oct-09-25 09:55AM	Wall Street Analysts See a 280.14% Upside in MBX Biosciences, Inc. (MBX): Can the Stock Really Move This High? (Zacks)
Oct-08-25 07:00AM	Biotech and Medical Tech Stocks Report Breakthrough Clinical Trial Updates (Newsfile)
Sep-29-25 08:00AM	MBX Biosciences to Participate in the Stifel 2025 Virtual Cardiometabolic Forum (GlobeNewswire)
09:15PM	Loading…
Sep-24-25 09:15PM	MBX Biosciences Announces Pricing of Upsized Public Offering (GlobeNewswire) +6.01% -13.78%
Sep-23-25 09:55AM	Wall Street Analysts Think MBX Biosciences, Inc. (MBX) Could Surge 88.55%: Read This Before Placing a Bet (Zacks) -5.20%
06:45AM	MBX to advance hypoparathyroidism drug to Phase III trial (Clinical Trials Arena)
04:54AM	FDA clears under-the-skin Keytruda; MBX shares double on study data (BioPharma Dive)
Sep-22-25 04:14PM	MBX Biosciences Announces Proposed Public Offering (GlobeNewswire) +100.00%
04:03PM	MBX Biosciences Stock Doubles On Promising New Thyroid Disease Treatment (Investor's Business Daily)
09:34AM	MBX Biosciences Catapults 125%, Hitting A Nine-Month High, On Thyroid Drug Promise (Investor's Business Daily)
08:28AM	MBX Biosciences' Experimental Drug Shows Promise In Hypoparathyroidism Study (Benzinga)
07:00AM	MBX Biosciences Announces Once-Weekly Canvuparatide Achieved Primary Endpoint in Phase 2 Trial with 63% Responder Rate at 12 Weeks; 79% Responder Rate at 6 Months in Open-Label Extension (GlobeNewswire)
Sep-19-25 04:18PM	MBX Biosciences to Provide Topline Results from its Phase 2 Trial of Potential Once-Weekly Canvuparatide for Hypoparathyroidism (HP) on Monday, September 22 (GlobeNewswire)
Sep-15-25 12:15PM	Top 3 Biotech Stocks to Watch According to BofA Global Research (Investing.com)
Sep-04-25 08:00AM	MBX Biosciences Doses First Participant in Phase 1 Trial of MBX 4291 for the Treatment of Obesity (GlobeNewswire) -10.28%
Aug-20-25 12:13AM	MBX Biosciences Submits IND for Once-Monthly Obesity Drug (Insider Monkey)
Aug-07-25 08:00AM	MBX Biosciences Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights (GlobeNewswire)
Aug-05-25 09:37AM	Block downgraded, Wayfair upgraded: Wall Street's top analyst calls (The Fly)
Jun-23-25 08:00AM	MBX Biosciences Appoints Andreas Moraitis, M.D., as Senior Vice President of Clinical Development (GlobeNewswire)
Jun-16-25 08:00AM	MBX Biosciences Announces IND Submission of MBX 4291, its Long-acting GLP1/GIP Receptor Co-agonist Prodrug for the Treatment of Obesity (GlobeNewswire)
Jun-10-25 08:00AM	MBX Biosciences to Present at the American Diabetes Association 85th Scientific Sessions (GlobeNewswire)
May-20-25 08:00AM	MBX Biosciences to Participate in June Investor Conferences (GlobeNewswire)
May-15-25 07:16AM	Microbix Reports Results for Q2 Fiscal 2025 (GlobeNewswire)
May-13-25 07:00AM	Microbix & Aurevia Introduce Novel EQA Scheme (GlobeNewswire) -7.81%
May-12-25 08:00AM	MBX Biosciences Reports First Quarter 2025 Financial Results and Recent Corporate Highlights (GlobeNewswire)
May-08-25 07:00AM	Microbix Schedules Release of Results for Q2 Fiscal 2025 (GlobeNewswire) +8.13%
May-05-25 07:00AM	Microbix's Clot-Buster Drug Project Advances (GlobeNewswire)
Apr-22-25 08:00AM	MBX Biosciences to Participate in Citizens and RBC May Investor Conferences (GlobeNewswire) +13.09%
Apr-07-25 08:00AM	MBX Biosciences Appoints Veteran Pharmaceutical Executive Steve Hoerter to Board of Directors (GlobeNewswire)
Mar-26-25 08:00AM	MBX Biosciences to Participate in the 24th Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Mar-17-25 08:00AM	MBX Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights (GlobeNewswire)
Mar-05-25 08:00AM	MBX Biosciences Announces Additions to Leadership Team (GlobeNewswire)
Mar-03-25 08:00AM	MBX Biosciences Completes Enrollment in Phase 2 Avail Trial of MBX 2109 (Canvuparatide) for Hypoparathyroidism (GlobeNewswire) +5.62%
Feb-18-25 08:00AM	MBX Biosciences to Participate in March Investor Conferences (GlobeNewswire)
Jan-23-25 08:00AM	MBX Biosciences to Participate in Upcoming February Investor Conferences (GlobeNewswire) +8.11%
Jan-07-25 11:47AM	MBX Biosciences' Investigational Drug For Weight Loss Surgery-Related Low Blood Sugar Shows Encouraging Action (Benzinga) -10.32%
07:00AM	MBX Biosciences Announces Positive Phase 1 Topline Results for MBX 1416 for the Treatment of Post-bariatric Hypoglycemia (GlobeNewswire)
Dec-18-24 08:00AM	MBX Biosciences to Participate in 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-02-24 08:00AM	MBX Biosciences Announces MBX 2109 Phase 1 Study Results Published in The Journal of Clinical Endocrinology and Metabolism (GlobeNewswire) -6.59%
Nov-18-24 08:00AM	MBX Biosciences Announces Last Subject Last Visit in Phase 1 Trial of MBX 1416 for the Treatment of Post-Bariatric Hypoglycemia (GlobeNewswire) -6.76%
Nov-07-24 08:00AM	MBX Biosciences Reports Third Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
Oct-28-24 08:00AM	MBX Biosciences to Participate in Upcoming November Investor Conferences (GlobeNewswire) -6.50%
Oct-14-24 06:45AM	Opening Day: Another trio of biotech IPOs make Friday debut (TipRanks)
Sep-30-24 08:00AM	MBX Biosciences Presents MBX 2109 Phase 2 Avail Hypoparathyroidism Trial Rationale and Design at the ASBMR 2024 Annual Meeting (GlobeNewswire) +8.48%
Sep-23-24 07:05PM	Deep Track Capital, LP's Strategic Acquisition in MBX Biosciences Inc (GuruFocus.com)
Sep-18-24 03:19AM	OrbiMed Advisors LLC Acquires New Stake in MBX Biosciences Inc (GuruFocus.com)
Sep-16-24 04:05PM	MBX Biosciences Announces Closing of Upsized Initial Public Offering, Including Full Exercise of Underwriters' Option to Purchase Additional Shares (GlobeNewswire) -8.46%
Sep-12-24 07:11PM	MBX Biosciences Announces Pricing of Initial Public Offering (GlobeNewswire)

MBX Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of peptide therapies for the treatment of endocrine and metabolic disorders. Its product candidates and programs include MBX 2109, MBX 1416, and obesity portfolio. The company was founded by Peter Kent Hawryluk and Richard D. DiMarchi in August 2018 and is headquartered in Carmel, IN.

Executive ChairpersonMr. Steven L. Hoerter

CEOMr. Peter Kent Hawryluk MBA

Chief Medical OfficerDr. Salomon Azoulay M.D.

Interim Chief Financial OfficerMr. John W. Smither CPA

Senior Vice President of Investor Relations & Corporate CommunicationsMr. Pete De Spain

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Bartram Richard	Former Officer	May 13 '26	Proposed Sale	36.95	15,000	554,296		May 13 04:17 PM
Azoulay Salomon	Chief Medical Officer	May 08 '26	Option Exercise	11.65	70,003	815,348	69,769	May 11 04:01 PM
Azoulay Salomon	Chief Medical Officer	May 08 '26	Sale	38.36	70,003	2,685,515	14,769	May 11 04:01 PM
Bartram Richard	Former Officer	May 11 '26	Proposed Sale	44.08	22,500	991,901		May 11 03:54 PM
Azoulay Salomon	Officer	May 08 '26	Proposed Sale	38.37	70,003	2,685,679		May 08 04:10 PM
Azoulay Salomon	Chief Medical Officer	May 06 '26	Sale	29.54	231	6,824	14,769	May 08 04:02 PM
Hawryluk P. Kent	President & CEO	May 06 '26	Sale	29.54	607	17,931	727,667	May 08 04:00 PM
Bartram Richard	Former Officer	May 08 '26	Proposed Sale	37.96	10,000	379,562		May 08 12:21 PM
Bartram Richard	Former Officer	May 07 '26	Proposed Sale	32.20	10,000	322,050		May 07 12:47 PM
Hawryluk P. Kent	Officer	May 06 '26	Proposed Sale	29.54	607	17,934		May 06 03:29 PM
Azoulay Salomon	Officer	May 06 '26	Proposed Sale	29.54	231	6,825		May 06 03:12 PM
Bartram Richard	Former Officer	May 01 '26	Proposed Sale	31.80	5,000	159,000		May 01 02:59 PM
Bartram Richard	Former Officer	Apr 22 '26	Proposed Sale	32.75	10,423	341,378		Apr 22 11:59 AM
Bartram Richard	Former Officer	Mar 25 '26	Proposed Sale	28.48	1,061	30,217		Mar 25 03:20 PM
Bartram Richard	Former Officer	Mar 16 '26	Proposed Sale	30.05	10,000	300,471		Mar 16 02:47 PM
Hawryluk P. Kent	President & CEO	Mar 13 '26	Buy	28.41	18,500	525,663	486,777	Mar 16 08:02 AM
Hawryluk P. Kent	President & CEO	Feb 26 '26	Option Exercise	16.00	28,768	460,288	728,274	Feb 27 04:07 PM
CORNELIUS JAMES M	Former Director	Jan 12 '26	Proposed Sale	35.74	30,864	1,102,991		Jan 12 03:41 PM
Hawryluk P. Kent	President & CEO	Oct 24 '25	Option Exercise	3.25	182,859	594,292	664,256	Oct 28 08:03 AM
Hawryluk P. Kent	President & CEO	Oct 20 '25	Buy	13.64	20,000	272,790	468,277	Oct 21 05:43 PM
Hoerter Steven L.	Director	Oct 17 '25	Buy	13.25	20,000	264,984	20,000	Oct 20 04:44 PM
Heron Patrick J	Director	Sep 26 '25	Buy	18.00	666,666	11,999,988	5,219,440	Sep 30 04:59 PM

Open in Screener

ARQT

Arcutis Biotherapeutics Inc

May 22 • 04:00PM ET

20.86

-0.15 -0.71 %

Healthcare • Biotechnology • USA • Mid • NASD

ARQT Arcutis Biotherapeutics Inc daily Stock Chart

Peers: KRYS INCY ANAB ZURA VRCA

| Held by: XBI VTI IWM VXF IWO IBB VTWO SCHA VHT FESM

Index	RUT	P/E	-	EPS (ttm)	-0.03	Insider Own	11.57%	Shs Outstand	125.04M	Perf Week	-2.16%
Market Cap	2.61B	Forward P/E	19.52	EPS next Y	1.07	Insider Trans	-1.81%	Shs Float	110.42M	Perf Month	-8.75%
Enterprise Value	2.50B	PEG	-	EPS next Q	0.04	Inst Own	98.39%	Short Float	15.29%	Perf Quarter	-20.71%
Income	-2.38M	P/S	6.28	EPS this Y	253.13%	Inst Trans	1.96%	Short Ratio	10.87	Perf Half Y	-25.21%
Sales	415.62M	P/B	13.75	EPS next Y	436.89%	ROA	-0.59%	Short Interest	16.88M	Perf YTD	-28.17%
Book/sh	1.52	P/C	11.63	EPS next 5Y	-	ROE	-1.43%	52W High	31.77 -34.34%	Perf Year	52.71%
Cash/sh	1.79	P/FCF	96.93	EPS past 3/5Y	71.80% 49.34%	ROIC	-0.80%	52W Low	12.72 63.99%	Perf 3Y	111.99%
Dividend Est.	-	EV/EBITDA	405.78	Sales past 3/5Y	367.27% -	Gross Margin	90.94%	Volatility	5.06% 5.47%	Perf 5Y	-17.71%
Dividend TTM	-	EV/Sales	6.01	EPS Y/Y TTM	98.21%	Oper. Margin	0.77%	ATR (14)	1.15	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	2.46	Sales Y/Y TTM	95.29%	Profit Margin	-0.57%	RSI (14)	43.11	Recom	1.25
Dividend Gr. 3/5Y	- -	Current Ratio	2.68	EPS Q/Q	56.09%	SMA20	-4.52%	Beta	1.54	Target Price	34.62
Payout	-	Debt/Eq	0.60	Sales Q/Q	60.07%	SMA50	-8.20%	Rel Volume	0.71	Prev Close	21.01
Employees	354	LT Debt/Eq	0.56	Earnings	May 06 AMC	SMA200	-10.62%	Avg Volume	1.55M	Price	20.86
IPO	Jan 31, 2020	Option/Short	Yes / Yes	EPS/Sales Surpr.	-39.97% 1.66%	Trades		Volume	1,161,973	Change	-0.71%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-25-25	Initiated	Goldman	Neutral	$18
Dec-30-24	Initiated	H.C. Wainwright	Buy	$19
Aug-28-24	Initiated	Jefferies	Buy	$15
Jan-03-24	Upgrade	Mizuho	Neutral → Buy	$4 → $8
Oct-26-23	Downgrade	Mizuho	Buy → Neutral	$57 → $4
Oct-13-23	Downgrade	Goldman	Buy → Neutral	$32 → $6
Sep-07-22	Initiated	Needham	Buy	$46
Mar-17-22	Initiated	Goldman	Buy	$45
Jun-30-21	Initiated	Mizuho	Buy	$58
May-27-21	Upgrade	Morgan Stanley	Equal-Weight → Overweight	$52
Nov-09-20	Upgrade	Goldman	Neutral → Buy	$34 → $36
Oct-08-20	Initiated	Truist	Buy	$38
Feb-25-20	Initiated	Guggenheim	Buy	$36
Feb-25-20	Initiated	Goldman	Neutral	$30
Feb-25-20	Initiated	Cowen	Outperform	$55
Feb-25-20	Initiated	Cantor Fitzgerald	Overweight	$50

Show Previous Ratings

May-08-26 04:00PM	Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
May-07-26 08:30AM	Arcutis Biotherapeutics, Inc. Q1 2026 Earnings Call Summary (Moby) -14.52%
May-06-26 04:00PM	Arcutis Announces First Quarter 2026 Financial Results and Provides Business Update (GlobeNewswire)
Apr-27-26 08:00AM	Arcutis Submits Supplemental New Drug Application to the FDA for ZORYVE (roflumilast) Cream 0.05% to Expand Indication for Treatment of Atopic Dermatitis to Infants Down to 3 Months (GlobeNewswire)
Apr-22-26 08:00AM	Arcutis' ZORYVE (roflumilast) Cream Receives Strong Recommendation in American Academy of Dermatology First-Ever Pediatric Atopic Dermatitis Guidelines (GlobeNewswire)
04:00PM	Loading…
Apr-15-26 04:00PM	Arcutis to Report First Quarter 2026 Financial Results and Host Conference Call on May 6, 2026 (GlobeNewswire)
Mar-31-26 04:00PM	Arcutis Management to Present at the 25th Annual Needham Virtual Healthcare Conference (GlobeNewswire) +10.45%
Mar-28-26 11:00AM	Arcutis Presents New Phase 2 Results in Infants with Atopic Dermatitis in Late-Breaking Session Today at the 2026 American Academy of Dermatology Annual Meeting (GlobeNewswire)
Mar-26-26 05:20PM	Arcutis Biotherapeutics Shows Market Leadership With Jump To 82 RS Rating (Investor's Business Daily) -5.18%
Mar-18-26 08:00AM	Arcutis to Present New Clinical Data in a Late-Breaking Podium Presentation and Scientific Posters at the 2026 American Academy of Dermatology Annual Meeting (GlobeNewswire)
Mar-10-26 09:00AM	Arcutis Announces Publication of Positive Long-Term Safety and Efficacy Data with ZORYVE (roflumilast) Cream 0.05% for Treatment of Mild-to-Moderate Atopic Dermatitis in Children Ages 2-5 in Pediatric Dermatology (GlobeNewswire)
Mar-06-26 10:20AM	Guggenheim Raises Its Price Target on Arcutis Biotherapeutics, Inc. (ARQT) to $35 and Maintains a Buy Rating (Insider Monkey)
Mar-05-26 09:00AM	Arcutis Announces Promotion of Mas Matsuda to Executive Vice President and Chief Legal Officer to Support Next Phase of Growth (GlobeNewswire)
Mar-04-26 08:09AM	Arcutis Biotherapeutics Spotlights ZORYVE Surge, 2025 Revenue Beat and Key FDA Milestones at TD Cowen (MarketBeat)
Mar-03-26 08:00AM	Arcutis Begins Enrolling Phase 1a/1b Study Evaluating ARQ-234, a CD200R Agonist, in Healthy Volunteers and Adults With Atopic Dermatitis (GlobeNewswire)
04:00PM	Loading…
Feb-27-26 04:00PM	Arcutis Management to Present at TD Cowen's 46th Annual Health Care Conference (GlobeNewswire) -5.60% -8.19%
Feb-26-26 08:30AM	Arcutis Biotherapeutics, Inc. Q4 2025 Earnings Call Summary (Moby) +5.78%
12:04AM	Arcutis Biotherapeutics Inc (ARQT) Q4 2025 Earnings Call Highlights: Record Revenue Growth and ... (GuruFocus.com)
Feb-25-26 07:25PM	Arcutis Biotherapeutics, Inc. (ARQT) Surpasses Q4 Earnings and Revenue Estimates (Zacks)
06:32PM	Arcutis Biotherapeutics Q4 Earnings Call Highlights (MarketBeat)
04:00PM	Arcutis Announces Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update (GlobeNewswire)
Feb-24-26 09:15AM	Professional Golfer Max Homa Joins Arcutis' Free to Be Me Campaign, Urging Individuals with Seborrheic Dermatitis to Tee Up a Conversation with Their Healthcare Provider About Long-Term Treatments (GlobeNewswire)
07:22AM	Arcutis Biotherapeutics Inc (ARQT) Q4 2025: Everything You Need To Know Ahead Of Earnings (GuruFocus.com)
Feb-19-26 10:00AM	Castle Biosciences, Inc. (CSTL) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release (Zacks)
Feb-18-26 10:00AM	Arcutis Biotherapeutics, Inc. (ARQT) Earnings Expected to Grow: Should You Buy? (Zacks)
Feb-17-26 10:05AM	Arcutis Biotherapeutics to Report Q4 Earnings: What's in the Cards? (Zacks)
Feb-11-26 06:02PM	Arcutis Biotherapeutics Touts ZORYVE Expansion, New Indications and 2026 Cash-Flow Breakeven Goal (MarketBeat)
Feb-10-26 08:32AM	Implied Volatility Surging for Arcutis Biotherapeutics Stock Options (Zacks)
Feb-05-26 04:00PM	Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Feb-02-26 08:00AM	Arcutis Announces Positive Topline Results for INTEGUMENT-INFANT Phase 2 Trial of ZORYVE (roflumilast) Cream 0.05% in Infants with Mild to Moderate Atopic Dermatitis (GlobeNewswire)
08:16AM	Loading…
Jan-27-26 08:16AM	Arcutis Biotherapeutics announces termination of promotion agreement with Kowa (TipRanks)
Jan-26-26 08:00AM	Arcutis Biotherapeutics, Inc. Announces Termination of Promotion Agreement with Kowa (GlobeNewswire)
Jan-22-26 04:00PM	Arcutis to Report Fourth Quarter and Full Year 2025 Financial Results and Present at Upcoming Investor Conference (GlobeNewswire)
Jan-21-26 08:00AM	Nationwide Survey Underscores Concerns with Use of Topical Steroids and Need for Long-Term Treatment Strategies Facing the 46 Million Americans with Chronic Inflammatory Skin Conditions (GlobeNewswire)
Jan-13-26 04:21AM	Strength Seen in ANI (ANIP): Can Its 10.6% Jump Turn into More Strength? (Zacks)
Jan-12-26 08:00AM	Arcutis Highlights 2026 Strategic Priorities and Anticipated Milestones (GlobeNewswire) -5.10%
Dec-19-25 09:40AM	Are Medical Stocks Lagging Compass Therapeutics, Inc. (CMPX) This Year? (Zacks)
Dec-18-25 03:43AM	Zacks Industry Outlook Arcutis, Amicus and ANI (Zacks)
Dec-17-25 02:19PM	5 Biotech Stocks to Watch for Potential Upside (Zacks)
Dec-14-25 09:35AM	This Biotech Stock Could Cure Your Portfolio's Pain (Motley Fool)
Dec-10-25 12:00PM	What Makes Arcutis Biotherapeutics, Inc. (ARQT) a Strong Momentum Stock: Buy Now? (Zacks)
Dec-08-25 04:00PM	Arcutis Strengthens Board of Directors with New Appointment of Amit Munshi and Honors Retirement of Bhaskar Chaudhuri (GlobeNewswire)
10:39AM	PRAX Stock Skyrockets 520% in 3 Months: Here's What You Need to Know (Zacks)
10:30AM	Incyte's Rare Blood Cancer Therapy Gets FDA's Breakthrough Status (Zacks)
Dec-05-25 10:37AM	ABSI Stock Up on Initiating Dosing in Androgenetic Alopecia Study (Zacks)
10:34AM	CAPR Stock Skyrockets 282% in a Week: Here's What You Need to Know (Zacks)
Dec-04-25 09:47AM	Zoetis Stock Plummets 24.8% YTD: Here's What You Need to Know (Zacks)
Dec-03-25 10:23AM	PCRX's Iovera Outperforms RFA Therapy in Pilot Study for Low Back Pain (Zacks)
10:01AM	AZN's Baxdrostat Gets FDA Priority Tag for Uncontrolled Hypertension (Zacks)
09:40AM	Is BrightSpring Health Services, Inc. (BTSG) Outperforming Other Medical Stocks This Year? (Zacks)
Dec-02-25 10:15AM	MIRM Enrolls First Patient in Phase II Fragile X Syndrome Study (Zacks)
10:12AM	Is the Options Market Predicting a Spike in Arcutis Biotherapeutics Stock? (Zacks)
10:09AM	JNJ Gets EU Nod for Imaavy in Generalized Myasthenia Gravis (Zacks)
Dec-01-25 11:41AM	ARCT Stock Plunges 59% in Three Months: Here's What You Need to Know (Zacks)
Nov-28-25 09:33AM	Netflix target cut, Five Below target raised: Wall Street's top analyst calls (The Fly)
Nov-25-25 11:10AM	NVO Stock Down as Rybelsus Misses Goals in 2 Alzheimer's Studies (Zacks)
10:43AM	Biogen Inks Research Deal With Dayra to Boost Immunology Pipeline (Zacks)
Nov-21-25 03:47AM	Why Shares in Arcutis Biotherapeutics Surged Again This Week (Motley Fool) +7.90%
Nov-20-25 11:38AM	COGT Stock Skyrockets 120% in a Month: Here's What You Need to Know (Zacks)
09:49AM	MRK HIV Regimen Meets Goal in New Study, Gains EU Nod for Keytruda SC (Zacks)
09:15AM	Arcutis Biotherapeutics, Inc. (ARQT) Soars to 52-Week High, Time to Cash Out? (Zacks)
Nov-19-25 10:06AM	VNDA Stock Jumps on Upbeat Tradipitant Data Cutting GLP-1 Side Effects (Zacks)
Nov-18-25 11:42AM	VTYX Stock Skyrockets 156% in a Month: Here's What You Need to Know (Zacks)
10:33AM	Alector Stock Plummets 63% in a Month: Here's What You Need to Know (Zacks)
Nov-17-25 09:41AM	Are Medical Stocks Lagging BrightSpring Health Services, Inc. (BTSG) This Year? (Zacks)
09:35AM	Arcutis Biotherapeutics, Inc. (ARQT) Recently Broke Out Above the 20-Day Moving Average (Zacks)
08:00AM	FDA Accepts Supplemental New Drug Application for Arcutis' ZORYVE (roflumilast) Cream 0.3% for the Treatment of Plaque Psoriasis in Children Ages 2 to 5 (GlobeNewswire)
Nov-15-25 08:00AM	CrowdStrike Leads Five Stocks To Watch Near Buy Points (Investor's Business Daily)
Nov-14-25 07:36AM	Kodiak Q3 Loss Wider Than Expected, Pipeline Development in Focus (Zacks) +9.36%
Nov-13-25 09:08AM	Novartis' Phase III Malaria Study Meets Key Non-Inferiority Endpoint (Zacks)
08:00AM	Arcutis Completes Enrollment in INTEGUMENT-INFANT Phase 2 Study Evaluating ZORYVE (roflumilast) Cream 0.05% in Infants with Atopic Dermatitis (GlobeNewswire)
Nov-11-25 10:37AM	Editas Q3 Loss Narrower Than Expected, Revenues Increase Y/Y (Zacks)
Nov-07-25 04:00PM	Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
11:27AM	Novavax Q3 Earnings & Revenues Beat Estimates, '25 Sales View Raised (Zacks)
11:22AM	ESPR's Q3 Earnings Lag Estimates, Revenues Rise Y/Y, Stock Down (Zacks)
10:53AM	PBYI's Q3 Earnings & Revenues Beat Estimates, 2025 Sales View Raised (Zacks)
Nov-06-25 11:23AM	ACAD Q3 Earnings Beat, Nuplazid & Daybue Drive Y/Y Revenue Growth (Zacks)
11:18AM	TEVA Q3 Earnings & Revenues Beat, Austedo Sales View Raised, Stock Up (Zacks)
Nov-05-25 11:27AM	MIRM's Q3 Earnings & Revenues Beat Estimates, 2025 View Tightened (Zacks)
10:01AM	Corcept Q3 Earnings & Revenues Lag Estimates, '25 View Cut, Stock Down (Zacks)
09:55AM	Wall Street Analysts Believe Arcutis Biotherapeutics (ARQT) Could Rally 26.53%: Here's is How to Trade (Zacks)
Nov-04-25 10:26AM	TGTX's Q3 Earnings & Revenues Trump Estimates, 2025 View Raised (Zacks)
08:00AM	Arcutis Announces Publication of Positive Long-Term Safety and Efficacy Data of ZORYVE (roflumilast) Foam 0.3% in Individuals with Seborrheic Dermatitis in American Journal of Clinical Dermatology (GlobeNewswire)
Oct-31-25 09:15AM	Arcutis Biotherapeutics, Inc. (ARQT) Hits Fresh High: Is There Still Room to Run? (Zacks)
Oct-30-25 12:00PM	What Makes Arcutis Biotherapeutics (ARQT) a New Strong Buy Stock (Zacks)
09:40AM	Is Grifols (GRFS) Stock Outpacing Its Medical Peers This Year? (Zacks)
09:15AM	Mother-Daughter Duo, Tori Spelling and Stella McDermott, Partner With Arcutis Biotherapeutics in the Free to Be Me Campaign, Urging People With Inflammatory Skin Conditions to Speak With Their Healthcare Provider About Long-Term Treatments (GlobeNewswire)
08:00AM	Arcutis Launches ZORYVE (roflumilast) Cream 0.05% for the Treatment of Mild to Moderate Atopic Dermatitis in Children Ages 2 to 5 (GlobeNewswire)
Oct-29-25 09:08AM	Arcutis (ARQT) Soars to Record High on Swing to Profitability, 'More-Than-Double' Revenues (Insider Monkey)
Oct-28-25 12:00PM	Here's Why This Biotherapeutics Company's Stock Surged Higher by 30% Today (Motley Fool) +27.04%
11:37AM	Arcutis Tops A Profit-Taking Zone After Smashing Forecasts. But There Was Another Surprise. (Investor's Business Daily)
09:35AM	Arcutis Biotherapeutics, Inc. (ARQT) Q3 Earnings and Revenues Surpass Estimates (Zacks)
08:30AM	Arcutis Outlines Strategy for Driving Sustainable Growth and Announces Third Quarter 2025 Financial Results (GlobeNewswire)
Oct-27-25 04:00PM	Arcutis to Present at Upcoming Investor Conferences (GlobeNewswire)
09:30AM	What To Expect From Arcutis Biotherapeutics Inc (ARQT) Q3 2025 Earnings (GuruFocus.com)
Oct-24-25 08:00AM	Arcutis to Present New Quality of Life and Long-Term Data with ZORYVE (roflumilast) Cream 0.15% and 0.05% for the Treatment of Atopic Dermatitis at the Fall Clinical Dermatology Conference (GlobeNewswire)
Oct-21-25 10:00AM	Arcutis Biotherapeutics, Inc. (ARQT) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release (Zacks)
Oct-06-25 08:00AM	FDA Approves Arcutis' ZORYVE (roflumilast) Cream 0.05% for the Treatment of Atopic Dermatitis in Children Ages 2 to 5 (GlobeNewswire)
06:41AM	Tarsus Pharmaceuticals (TARS) Moves 10.9% Higher: Will This Strength Last? (Zacks)
Oct-03-25 04:00PM	Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -6.26%

Arcutis Biotherapeutics, Inc. engages in the development and commercialization of treatments for dermatological diseases. Its pipeline consists of topical treatments for plaque psoriasis, atopic dermatitis, hand eczema, vitiligo, scalp psoriasis, alopecia areata, and seborrheic dermatitis. The company was founded by Bhaskar Chaudhuri and David W. Osborne in June 2016 and is headquartered in Westlake Village, CA.

PresidentMr. Todd Franklin Watanabe M.A.

Co-Founder & Director EmeritusDr. Bhaskar Chaudhuri Ph.D.

Senior VP & Chief Financial OfficerMs. Latha Vairavan

J.D.Mr. Masaru Matsuda Esq.

Ph.D.Dr. Patrick E. Burnett M.D.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Vairavan Latha	SVP Chief Financial Officer	May 11 '26	Sale	21.05	435	9,157	85,978	May 13 07:43 PM
Burnett Patrick	See Remarks	May 11 '26	Sale	21.05	222	4,673	120,244	May 13 07:42 PM
Patrick Burnett	Officer	May 11 '26	Proposed Sale	21.05	222	4,673		May 11 04:44 PM
Latha Vairavan	officer	May 11 '26	Proposed Sale	21.05	435	9,157		May 11 04:35 PM
Matsuda Masaru	See Remarks	May 04 '26	Sale	23.31	8,256	192,415	126,689	May 06 07:40 PM
Burnett Patrick	See Remarks	May 04 '26	Sale	23.61	684	16,150	120,466	May 06 06:15 PM
Vairavan Latha	SVP Chief Financial Officer	May 04 '26	Sale	23.61	1,341	31,662	86,413	May 06 06:13 PM
Watanabe Todd	See Remarks	May 04 '26	Sale	23.61	3,172	74,893	720,755	May 06 06:06 PM
Welgus Howard G.	Director	May 01 '26	Sale	22.99	7,144	164,220	32,600	May 05 08:21 PM
Patrick Burnett	Officer	May 04 '26	Proposed Sale	23.61	684	16,150		May 04 05:19 PM
Latha Vairavan	Officer	May 04 '26	Proposed Sale	23.61	1,341	31,662		May 04 05:18 PM
Todd Watanabe	Officer	May 04 '26	Proposed Sale	23.61	3,172	74,893		May 04 05:18 PM
Masaru Matsuda	officer	May 04 '26	Proposed Sale	23.31	8,256	192,416		May 04 05:05 PM
Howard Welgus	Director	May 01 '26	Proposed Sale	22.99	7,144	164,220		May 01 04:04 PM
Welgus Howard G.	Director	Apr 01 '26	Sale	23.88	10,000	238,801	39,744	Apr 03 05:46 PM
Howard Welgus	Director	Apr 01 '26	Proposed Sale	23.88	10,000	238,801		Apr 01 04:02 PM
Leonard Keith R	Director	Mar 02 '26	Option Exercise	8.28	39,272	325,231	61,395	Mar 04 04:17 PM
Leonard Keith R	Director	Mar 02 '26	Sale	25.39	39,272	997,195	22,123	Mar 04 04:17 PM
Welgus Howard G.	Director	Mar 02 '26	Sale	25.65	10,000	256,518	49,744	Mar 04 04:16 PM
Edwards Larry Todd	See Remarks	Mar 02 '26	Sale	25.18	3,687	92,846	175,178	Mar 03 08:43 PM
Watanabe Todd	See Remarks	Mar 02 '26	Sale	25.18	37,349	940,528	785,957	Mar 03 08:42 PM
Matsuda Masaru	See Remarks	Mar 02 '26	Sale	25.30	8,733	220,943	136,932	Mar 03 08:42 PM
Matsuda Masaru	See Remarks	Feb 27 '26	Sale	27.95	3,325	92,934	143,678	Mar 03 08:42 PM
Vairavan Latha	SVP Chief Financial Officer	Mar 02 '26	Sale	25.18	2,853	71,844	87,754	Mar 03 08:42 PM
Burnett Patrick	See Remarks	Mar 02 '26	Sale	25.18	6,287	158,320	121,150	Mar 03 08:41 PM
Masaru Matsuda	officer	Mar 02 '26	Proposed Sale	26.03	12,058	313,878		Mar 02 06:48 PM
Larry Todd Edwards	Officer	Mar 02 '26	Proposed Sale	25.18	3,687	92,846		Mar 02 06:22 PM
Todd Watanabe	Officer	Mar 02 '26	Proposed Sale	25.18	37,349	940,526		Mar 02 06:22 PM
Latha Vairavan	officer	Mar 02 '26	Proposed Sale	25.18	2,853	71,845		Mar 02 06:22 PM
Patrick Burnett	Officer	Mar 02 '26	Proposed Sale	25.18	6,287	158,320		Mar 02 06:21 PM
Keith Leonard	Board of Director	Mar 02 '26	Proposed Sale	25.39	39,272	997,195		Mar 02 05:59 PM
Howard Welgus	Director	Mar 02 '26	Proposed Sale	25.65	10,000	256,518		Mar 02 05:25 PM
Matsuda Masaru	See Remarks	Feb 02 '26	Sale	25.28	40,638	1,027,293	110,003	Feb 04 08:35 PM
Burnett Patrick	See Remarks	Feb 04 '26	Sale	25.81	9,794	252,748	80,651	Feb 04 07:30 PM
Burnett Patrick	See Remarks	Feb 02 '26	Sale	25.50	3,675	93,707	90,445	Feb 04 07:30 PM
Watanabe Todd	See Remarks	Feb 02 '26	Sale	25.50	19,833	505,710	721,306	Feb 04 07:25 PM
Vairavan Latha	SVP Chief Financial Officer	Feb 02 '26	Sale	25.50	1,320	33,658	63,607	Feb 04 07:24 PM
Welgus Howard G.	Director	Feb 02 '26	Sale	25.05	10,000	250,483	59,744	Feb 04 07:23 PM
Edwards Larry Todd	See Remarks	Feb 02 '26	Sale	25.50	2,052	52,323	148,865	Feb 04 07:21 PM
Patrick Burnett	Officer	Feb 04 '26	Proposed Sale	25.81	9,794	252,748		Feb 04 04:52 PM
Masaru Matsuda	officer	Feb 02 '26	Proposed Sale	25.28	40,638	1,027,275		Feb 02 06:19 PM
Todd Edwards	Officer	Feb 02 '26	Proposed Sale	25.50	2,052	52,323		Feb 02 06:17 PM
Latha Vairavan	Officer	Feb 02 '26	Proposed Sale	25.50	1,320	33,658		Feb 02 06:15 PM
Patrick Burnett	Officer	Feb 02 '26	Proposed Sale	25.50	3,675	93,707		Feb 02 05:48 PM
Todd Frank Watanabe	officer	Feb 02 '26	Proposed Sale	25.50	19,833	505,710		Feb 02 05:41 PM
Howard Welgus	Director	Feb 02 '26	Proposed Sale	25.05	10,000	250,483		Feb 02 05:04 PM
Burnett Patrick	See Remarks	Jan 05 '26	Sale	28.98	2,490	72,166	94,120	Jan 07 05:46 PM
Welgus Howard G.	Director	Jan 02 '26	Sale	28.96	10,000	289,606	69,744	Jan 06 05:31 PM
Patrick Burnett	Officer	Jan 05 '26	Proposed Sale	28.98	2,490	72,166		Jan 05 04:01 PM
Burnett Patrick	See Remarks	Dec 31 '25	Sale	29.20	1,697	49,560	96,610	Jan 02 06:12 PM
Howard Welgus	Director	Jan 02 '26	Proposed Sale	28.96	10,000	289,606		Jan 02 04:00 PM
Patrick Burnett	Officer	Dec 31 '25	Proposed Sale	29.21	1,697	49,561		Dec 31 04:01 PM
Burnett Patrick	See Remarks	Dec 15 '25	Option Exercise	3.64	11,500	41,860	109,807	Dec 17 05:53 PM
Burnett Patrick	See Remarks	Dec 15 '25	Sale	28.94	11,500	332,851	98,307	Dec 17 05:53 PM
Patrick Burnett	Officer	Dec 15 '25	Proposed Sale	28.94	11,500	332,851		Dec 15 04:07 PM
Matsuda Masaru	See Remarks	Dec 01 '25	Sale	30.23	1,657	50,091	150,641	Dec 03 05:24 PM
Welgus Howard G.	Director	Dec 01 '25	Sale	30.21	10,000	302,133	79,744	Dec 03 05:23 PM
Howard Welgus	Director	Dec 01 '25	Proposed Sale	30.21	10,000	302,133		Dec 01 04:07 PM
Masaru Matsuda	Officer	Dec 01 '25	Proposed Sale	30.23	1,657	50,091		Dec 01 04:06 PM
LIN SUE-JEAN	Director	Nov 24 '25	Option Exercise	8.31	25,272	210,011	52,007	Nov 25 06:27 PM
LIN SUE-JEAN	Director	Nov 24 '25	Sale	30.78	25,272	777,956	26,735	Nov 25 06:27 PM
Watanabe Todd	See Remarks	Nov 24 '25	Sale	30.36	48,945	1,485,755	740,537	Nov 24 06:45 PM
Watanabe Todd	See Remarks	Nov 21 '25	Sale	30.00	1,055	31,650	793,838	Nov 24 06:45 PM
Sue-Jean Lin	Director	Nov 24 '25	Proposed Sale	30.78	25,272	777,956		Nov 24 04:01 PM
Todd Franklin Watanabe	Officer	Nov 24 '25	Proposed Sale	30.36	48,945	1,485,755		Nov 24 03:55 PM
Matsuda Masaru	See Remarks	Nov 19 '25	Sale	28.29	2,550	72,135	151,476	Nov 21 06:34 PM
Gilbert Halley E	Director	Nov 20 '25	Option Exercise	7.51	12,220	91,772	38,655	Nov 21 06:21 PM
Gilbert Halley E	Director	Nov 20 '25	Sale	27.55	16,532	455,442	22,123	Nov 21 06:21 PM
Todd Franklin Watanabe	Officer	Nov 21 '25	Proposed Sale	30.00	1,055	31,650		Nov 21 04:49 PM
Halley Gilbert	Director	Nov 20 '25	Proposed Sale	27.55	16,532	455,442		Nov 20 04:24 PM
Masaru Matsuda	Officer	Nov 19 '25	Proposed Sale	28.29	2,550	72,133		Nov 19 04:20 PM
Krishnamohan Neha	Director	Nov 13 '25	Option Exercise	8.28	39,272	325,231	62,627	Nov 17 07:56 PM
Krishnamohan Neha	Director	Nov 13 '25	Sale	23.20	40,504	939,494	22,123	Nov 17 07:56 PM
Neha Krishnamohan	Director	Nov 13 '25	Proposed Sale	23.19	40,504	939,273		Nov 13 04:05 PM
Edwards Larry Todd	See Remarks	Nov 06 '25	Sale	25.16	29,131	732,927	150,193	Nov 10 05:42 PM
Burnett Patrick	See Remarks	Nov 06 '25	Option Exercise	3.64	17,250	62,790	115,575	Nov 10 05:41 PM
Burnett Patrick	See Remarks	Nov 06 '25	Sale	24.18	17,250	417,145	98,325	Nov 10 05:41 PM
Patrick Burnett	Officer	Nov 06 '25	Proposed Sale	24.18	17,250	417,145		Nov 06 05:49 PM
Burnett Patrick	See Remarks	Nov 05 '25	Sale	23.72	3,864	91,643	98,325	Nov 05 06:57 PM
Burnett Patrick	See Remarks	Nov 03 '25	Sale	24.72	2,622	64,806	102,189	Nov 05 06:57 PM
Welgus Howard G.	Director	Nov 03 '25	Sale	25.27	10,000	252,669	89,744	Nov 05 06:24 PM
Vairavan Latha	SVP Chief Financial Officer	Nov 03 '25	Sale	24.72	88	2,175	64,927	Nov 05 06:24 PM
Watanabe Todd	See Remarks	Nov 03 '25	Sale	24.72	11,547	285,399	794,893	Nov 05 06:23 PM
Matsuda Masaru	See Remarks	Nov 03 '25	Sale	24.72	7,208	178,156	154,026	Nov 05 06:23 PM
Patrick Burnett	Officer	Nov 05 '25	Proposed Sale	23.72	3,846	91,216		Nov 05 05:29 PM
Masaru Matsuda	Officer	Nov 03 '25	Proposed Sale	24.72	7,208	178,155		Nov 03 05:49 PM
Latha Vairavan	Officer	Nov 03 '25	Proposed Sale	24.72	88	2,175		Nov 03 05:48 PM
Todd Franklin Watanabe	Officer	Nov 03 '25	Proposed Sale	24.72	11,547	285,399		Nov 03 05:47 PM
Patrick Burnett	Officer	Nov 03 '25	Proposed Sale	24.72	2,622	64,806		Nov 03 05:47 PM
Howard Welgus	Director	Nov 03 '25	Proposed Sale	25.27	10,000	252,669		Nov 03 04:52 PM
Watanabe Todd	See Remarks	Oct 28 '25	Sale	25.03	40,000	1,001,032	806,440	Oct 30 07:02 PM
Todd F watanabe	officer	Oct 28 '25	Proposed Sale	25.03	40,000	1,001,033		Oct 28 04:06 PM
Edwards Larry Todd	See Remarks	Oct 02 '25	Sale	20.04	4,504	90,263	178,897	Oct 06 03:15 PM
Watanabe Todd	See Remarks	Oct 01 '25	Sale	19.33	24,261	469,074	867,179	Oct 03 05:02 PM
Watanabe Todd	See Remarks	Oct 02 '25	Sale	20.04	20,739	415,574	846,440	Oct 03 05:02 PM
Welgus Howard G.	Director	Oct 01 '25	Option Exercise	1.68	9,538	16,030	109,744	Oct 03 05:01 PM
Welgus Howard G.	Director	Oct 01 '25	Sale	18.92	10,000	189,227	99,744	Oct 03 05:01 PM
Todd Franklin Watanabe	Officer	Oct 02 '25	Proposed Sale	20.04	20,739	415,574		Oct 02 04:43 PM
Larry Todd Edwards	officer	Oct 02 '25	Proposed Sale	20.04	4,504	90,263		Oct 02 04:41 PM
Todd Franklin Watanabe	Officer	Oct 01 '25	Proposed Sale	19.33	24,261	469,074		Oct 01 05:35 PM

MIRM

Mirum Pharmaceuticals Inc

MBX

MBX Biosciences Inc

ARQT

Arcutis Biotherapeutics Inc

Upgrade your Finviz experience